Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yao Wang, Kaiyu Huang, Sijia Sun, Yahong Deng & Xuefeng Xie. (2022) Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer. Risk Management and Healthcare Policy 15, pages 351-359.
Read now
Read now
Bo Gao, Heinz-Josef Klumpen & Howard Gurney. (2008) Dose calculation of anticancer drugs. Expert Opinion on Drug Metabolism & Toxicology 4:10, pages 1307-1319.
Read now
Read now
Articles from other publishers (9)
Marco Ravanelli, Giorgio M. Agazzi, Balaji Ganeshan, Elisa Roca, Elena Tononcelli, Valeria Bettoni, Alberto Caprioli, Andrea Borghesi, Alfredo Berruti, Roberto Maroldi & Davide Farina. (2018) CT texture analysis as predictive factor in metastatic lung adenocarcinoma treated with tyrosine kinase inhibitors (TKIs). European Journal of Radiology 109, pages 130-135.
Crossref
Crossref
Juhong Jiang, Yingying Gu, Jing Liu, Ruibin Wu, Lin Fu, Jin Zhao & Yubao Guan. (2016) Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs. Lung Cancer 102, pages 101-107.
Crossref
Crossref
Hye Ryun Kim, Byoung Chul Cho, Hyo Sup Shim, Sun Min Lim, Se Kyu Kim, Joon Chang, Dae Joon Kim & Joo Hang Kim. (2014) Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer 83:3, pages 374-382.
Crossref
Crossref
Philip T. CagleRandall J. Olsen. (2012) Verifying the Role of Surgical Pathologists in the Precision Medicine of Lung Cancer. Archives of Pathology & Laboratory Medicine 137:9, pages 1176-1178.
Crossref
Crossref
Philip T. CagleTimothy Craig Allen. (2012) Lung Cancer Genotype-Based Therapy and Predictive Biomarkers: Present and Future. Archives of Pathology & Laboratory Medicine 136:12, pages 1482-1491.
Crossref
Crossref
Punit Marathe, Yuwei Tang, Bogdan Sleczka, David Rodrigues, Ashvinikumar Gavai, Tai Wong, Lisa Christopher & Hongjian Zhang. (2010) Preclinical Pharmacokinetics and In Vitro Metabolism of BMS-690514, a Potent Inhibitor of EGFR and VEGFR2. Journal of Pharmaceutical Sciences 99:8, pages 3579-3593.
Crossref
Crossref
Elisa Benedettini, Lynette M. Sholl, Michael Peyton, John Reilly, Christopher Ware, Lenora Davis, Natalie Vena, Dyane Bailey, Beow Y. Yeap, Michelangelo Fiorentino, Azra H. Ligon, Bo-Sheng Pan, Victoria Richon, John D. Minna, Adi F. Gazdar, Giulio Draetta, Silvano Bosari, Lucian R. Chirieac, Bart Lutterbach & Massimo Loda. (2010) Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis. The American Journal of Pathology 177:1, pages 415-423.
Crossref
Crossref
Chih-Hsin Yang, Lorinda Simms, Keunchil Park, Jin Soo Lee, Giorgio Scagliotti & Mauro Orlando. (2010) Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung Cancer: Results of an Exploratory Subgroup Analysis of a Phase III Trial. Journal of Thoracic Oncology 5:5, pages 688-695.
Crossref
Crossref
Tiziana Servidei, Anna Riccardi, Simona Mozzetti, Cristiano Ferlini & Riccardo Riccardi. (2008) Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. International Journal of Cancer 123:12, pages 2939-2949.
Crossref
Crossref